Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Share-based Compensation (2020 - 2025)

Mirum Pharmaceuticals has reported Share-based Compensation over the past 6 years, most recently at $19.0 million for Q4 2025.

  • Quarterly results put Share-based Compensation at $19.0 million for Q4 2025, up 43.58% from a year ago — trailing twelve months through Dec 2025 was $71.4 million (up 47.44% YoY), and the annual figure for FY2025 was $71.4 million, up 47.44%.
  • Share-based Compensation for Q4 2025 was $19.0 million at Mirum Pharmaceuticals, up from $18.1 million in the prior quarter.
  • Over the last five years, Share-based Compensation for MIRM hit a ceiling of $19.0 million in Q4 2025 and a floor of $4.8 million in Q2 2021.
  • Median Share-based Compensation over the past 5 years was $8.5 million (2023), compared with a mean of $10.2 million.
  • Biggest five-year swings in Share-based Compensation: soared 116.31% in 2021 and later decreased 6.84% in 2022.
  • Mirum Pharmaceuticals' Share-based Compensation stood at $5.6 million in 2021, then grew by 23.94% to $6.9 million in 2022, then surged by 40.95% to $9.7 million in 2023, then surged by 36.33% to $13.3 million in 2024, then soared by 43.58% to $19.0 million in 2025.
  • The last three reported values for Share-based Compensation were $19.0 million (Q4 2025), $18.1 million (Q3 2025), and $18.5 million (Q2 2025) per Business Quant data.